Evaluating heart issues in cancer patients
Evaluation and Management of Cardio Toxicity in Oncologic Patients
This study is trying to find out how to spot and manage heart problems in cancer patients and see if certain medications can help prevent these issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tel-Aviv Sourasky Medical Center Government |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Tel Aviv) |
| Trial ID | NCT02818517 on ClinicalTrials.gov |
What this trial studies
This study focuses on identifying and managing cardio toxicity in cancer patients, which can lead to serious heart problems. It aims to monitor patients through clinical evaluations, cardiac biomarkers, and echocardiograms to detect early signs of cardiac dysfunction. The study will create a registry of oncologic patients to better understand who is at increased risk for developing these heart issues. Additionally, it will explore the potential benefits of using ACE inhibitors and beta blockers in preventing cardiac dysfunction.
Who should consider this trial
Good fit: Ideal candidates for this study are cancer patients being evaluated in the cardio-oncology clinic at Tel Aviv Medical Center.
Not a fit: Patients who are not willing to provide informed consent or those who refuse to continue in the study may not benefit.
Why it matters
Potential benefit: If successful, this study could lead to improved management and prevention of heart problems in cancer survivors.
How similar studies have performed: Previous studies have suggested that interventions like ACE inhibitors and beta blockers may help prevent cardiac dysfunction in similar patient populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patient evaluated in the cardio-oncology clinic in Tel Aviv MC Exclusion Criteria: * In the prospective Study - patients not sign an informed consent form. Exclusion criteria experiment: Patient reluctance to continue the study.
Where this trial is running
Tel Aviv
- Tel Aviv Medical Center — Tel Aviv, Israel (Recruiting)
Study contacts
- Principal investigator: Udi Chorin, MD — Tel Aviv MC
- Study coordinator: Michal Laufer Perl, MD
- Email: michalpela@gmail.com
- Phone: 972-527360430
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.